Karyopharm Therapeutics (KPTI) Cash & Equivalents (2012 - 2025)

Karyopharm Therapeutics has reported Cash & Equivalents for 14 years, with the latest figure at $60.5 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 38.41% year-over-year to $60.5 million; the trailing twelve-month figure through Dec 2025 stood at $60.5 million (down 38.41% YoY), and the FY2025 full-year result was $60.5 million, down 38.41% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $60.5 million, up from $37.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $98.3 million in Q4 2024, with the low at $545000.0 in Q3 2023.
• Historically, Cash & Equivalents has averaged $39.6 million across 5 years, with a median of $36.3 million in 2025.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 99.26% — and 2024, when it soared 13262.94%.
• Karyopharm Therapeutics' Cash & Equivalents stood at $6.3 million in 2021, then tumbled by 83.24% to $1.1 million in 2022, then jumped by 4808.93% to $52.2 million in 2023, then surged by 88.2% to $98.3 million in 2024, then tumbled by 38.41% to $60.5 million in 2025.
• The last three Cash & Equivalents figures came in at $60.5 million (Q4 2025), $37.7 million (Q3 2025), and $34.9 million (Q2 2025), per Business Quant data.